TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33255613

Group type: EXPERIMENTAL
Intervention: Short-wavelength narrow-bandwidth light
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long-wavelength narrow-bandwidth light
Number of subjects: 0
Study: 33255658

Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine (T-DM1) combined with non-pegylated liposomal doxorubicin (NPLD)
Number of subjects: 0
Study: 33256053

Group type: EXPERIMENTAL
Intervention: Cognitive conflicts in BPD patients
Number of subjects: 0
Study: 33256377

Group type: EXPERIMENTAL
Intervention: Eltrombopag (EPAG) 50 mg/day to a maximum of 150 mg/day for 16 weeks
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Eltrombopag (EPAG)
Number of subjects: 25
Study: 33256590

Group type: EXPERIMENTAL
Intervention: Peri-procedural management of edoxaban
Number of subjects: 1442
Study: 33256726

Group type: EXPERIMENTAL
Intervention: Cancer survivors
Number of subjects: 267153

Group type: EXPERIMENTAL
Intervention: Multiple myeloma
Number of subjects: 267153
Study: 33256769

Group type: EXPERIMENTAL
Intervention: Maternal Newborn Health Registry (MNHR) intervention
Number of subjects: 579140
Study: 33256772

Group type: EXPERIMENTAL
Intervention: Congenital anomalies (nervous system, musculoskeletal system, cleft lip and palate)
Number of subjects: 384
Study: 33256777

Group type: EXPERIMENTAL
Intervention: Four or more antenatal care (ANC) visits
Number of subjects: 0

Group type: COMPARATOR
Intervention: Infants born weighing < 1000 g
Number of subjects: 0

Group type: COMPARATOR
Intervention: Infants born weighing 1000-1499 g
Number of subjects: 0

Group type: COMPARATOR
Intervention: Infants born weighing 1500-2499 g
Number of subjects: 0

Group type: COMPARATOR
Intervention: Infants born preterm (< 37 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: One-week decrease in gestational age at delivery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bag/mask ventilation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antibiotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxygen
Number of subjects: 0
Study: 33256782

Group type: EXPERIMENTAL
Intervention: Babies born weighing ≥ 2500 g
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pakistan site
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zambian/Kenyan sites
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zambia/Kenya and India
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pakistan and Guatemala
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal factors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neonatal characteristics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 0
Study: 33256783

Group type: EXPERIMENTAL
Intervention: Population-based study across 7 sites in LMIC
Number of subjects: 573148

Group type: COMPARATOR
Intervention: Guatemala site
Number of subjects: 573148

Group type: COMPARATOR
Intervention: African sites
Number of subjects: 573148

Group type: COMPARATOR
Intervention: Asian sites
Number of subjects: 573148

Group type: EXPERIMENTAL
Intervention: Women with less education and access to antenatal care
Number of subjects: 573148

Group type: EXPERIMENTAL
Intervention: Major fetal causes of stillbirth
Number of subjects: 573148

Group type: EXPERIMENTAL
Intervention: Maternal conditions observed
Number of subjects: 573148
Study: 33256784

Group type: EXPERIMENTAL
Intervention: Short IDI (6-17 months)
Number of subjects: 181782

Group type: EXPERIMENTAL
Intervention: IDI of 37-60 months
Number of subjects: 181782

Group type: EXPERIMENTAL
Intervention: Long IDI (61-180 months)
Number of subjects: 181782

Group type: EXPERIMENTAL
Intervention: Short and long IDIs
Number of subjects: 181782

Group type: COMPARATOR
Intervention: Reference IDI (18-36 months)
Number of subjects: 181782
Study: 33256790

Group type: EXPERIMENTAL
Intervention: Care around Delivery (CAD) - 8 practices recommended as part of the Essential Newborn Care (ENC) package
Number of subjects: 150848

Group type: EXPERIMENTAL
Intervention: Delivery by skilled birth attendant, presence of fetal heart, delayed bathing
Number of subjects: 150848

Group type: EXPERIMENTAL
Intervention: Present indicators (8 practices) of CAD
Number of subjects: 150848
Study: 33256829

Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg IV on cycle 1 day 1 and carboplatin IV AUC=5 on cycle 1 day 8; trastuzumab for HER2-positive patients
Number of subjects: 38

Group type: COMPARATOR
Intervention: ECOG PS 1-2
Number of subjects: 38
Study: 33256890

Group type: EXPERIMENTAL
Intervention: IgG seroconversion
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Serologic assays
Number of subjects: 177
Study: 33257140

Group type: EXPERIMENTAL
Intervention: Exosomal microRNAs (mir-483-5p and mir-126-3p) from bile samples
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Exosomal microRNAs (mir-483-5p and mir-126-3p)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (nonmalignant biliary obstruction)
Number of subjects: 82
Study: 33257189

Group type: EXPERIMENTAL
Intervention: High myocardial oxygen demand
Number of subjects: 106
Study: 33257488

Group type: EXPERIMENTAL
Intervention: Patients with neurological manifestations
Number of subjects: 1342

Group type: COMPARATOR
Intervention: Patients without neurological manifestations
Number of subjects: 1342
Study: 33257493

Group type: EXPERIMENTAL
Intervention: Singing leaders' approach and experiences in lung choirs
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Singing leaders' experiences
Number of subjects: 20
Study: 33257972

Group type: EXPERIMENTAL
Intervention: Wearable cardioverter-defibrillator (WCD)
Number of subjects: 1157
Study: 33257977

Group type: EXPERIMENTAL
Intervention: First-line chemotherapy with fluoropyrimidine, oxaliplatin, and bevacizumab
Number of subjects: 151
Study: 33258025

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Obese participants without diabetes
Number of subjects: 45

Group type: COMPARATOR
Intervention: Lean individuals
Number of subjects: 45

Group type: COMPARATOR
Intervention: Endurance-trained athletes
Number of subjects: 45
Study: 33258331

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD) implantation
Number of subjects: 485

Group type: COMPARATOR
Intervention: Matched control patients (no ICD)
Number of subjects: 485
Study: 33258568

Group type: EXPERIMENTAL
Intervention: UCOPD
Number of subjects: 65

Group type: COMPARATOR
Intervention: no-COPD
Number of subjects: 65
Study: 33258687

Group type: EXPERIMENTAL
Intervention: Composite grading algorithm for the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individual item scores
Number of subjects: 0
Study: 33258745

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 28
Study: 33258792

Group type: EXPERIMENTAL
Intervention: mobile-assisted cognitive behavioral therapy for negative symptoms (mCBTn)
Number of subjects: 31
Study: 33258793

Group type: EXPERIMENTAL
Intervention: UPrEPU app for adherence monitoring
Number of subjects: 70
Study: 33258950

Group type: EXPERIMENTAL
Intervention: Ivacaftor
Number of subjects: 26

Group type: COMPARATOR
Intervention: CF Control
Number of subjects: 26
Study: 33258996

Group type: EXPERIMENTAL
Intervention: COVID-19 pandemic lockdown
Number of subjects: 1964
Study: 33259032

Group type: EXPERIMENTAL
Intervention: Checkpoint inhibition therapy using monoclonal antibodies against PD-1 or PD-L1
Number of subjects: 0
Study: 33259326

Group type: EXPERIMENTAL
Intervention: Peer support group intervention facilitated by PSWs (10 weekly 90-minute online workshops)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Peer support group intervention facilitated by PSWs
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (n=10)
Number of subjects: 20
Study: 33259448

Group type: EXPERIMENTAL
Intervention: Hand TOF
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Foot TOF
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MMEPs
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Comparison of Hand TOF and MMEP
Number of subjects: 20
Study: 33259460

Group type: EXPERIMENTAL
Intervention: Congruent SCS-VR
Number of subjects: 15

Group type: COMPARATOR
Intervention: Incongruent SCS-VR
Number of subjects: 15

Group type: COMPARATOR
Intervention: VR alone
Number of subjects: 15
Study: 33259484

Group type: EXPERIMENTAL
Intervention: Smart bracelet monitoring
Number of subjects: 100
Study: 33259589

Group type: EXPERIMENTAL
Intervention: Umbralisib (800 mg/d)
Number of subjects: 51
Study: 33259596

Group type: EXPERIMENTAL
Intervention: Bruton tyrosine kinase inhibitors (BTKi's)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Treatment naïve (TN)
Number of subjects: 2
Study: 33259782

Group type: EXPERIMENTAL
Intervention: TDS (120 µg/day levonorgestrel and 30 µg/day ethinyl estradiol)
Number of subjects: 2032

Group type: COMPARATOR
Intervention: Control group not applicable (single-arm study)
Number of subjects: 2032
Study: 33259845

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes mellitus (T2DM)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Type 1 diabetes mellitus (T1DM)
Number of subjects: 67
Study: 33259921

Group type: EXPERIMENTAL
Intervention: Epicutaneous immunotherapy for peanut allergy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33259932

Group type: EXPERIMENTAL
Intervention: 6 months of androgen deprivation therapy (ADT) concurrent with abiraterone acetate plus prednisone (AAP) once daily and radiation therapy (RT) to prostate and seminal vesicles
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 6 months of ADT concurrent with AAP and RT
Number of subjects: 37
Study: 33260072

Group type: EXPERIMENTAL
Intervention: Preoperative cortical brain infarcts
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: More complex shape of white matter hyperintensities
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Preoperative brain volumes, white matter hyperintensity volume, and cerebral perfusion
Number of subjects: 413
Study: 33261573

Group type: EXPERIMENTAL
Intervention: Fundus fluorescein angiography (FFA)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Combined examination of posterior pole, nasal, and inferior nasal fields
Number of subjects: 324
Study: 33261718

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 exposure (index patients)
Number of subjects: 11

Group type: COMPARATOR
Intervention: SARS-CoV-2 exposure (contacts)
Number of subjects: 11

Group type: COMPARATOR
Intervention: SARS-CoV-2 exposure (couples and controls)
Number of subjects: 11
Study: 33261814

Group type: EXPERIMENTAL
Intervention: Semi-automated plaque characterization (SAPC) analysis via coronary computed tomographic angiography (CTA)
Number of subjects: 259
Study: 33262134

Group type: EXPERIMENTAL
Intervention: HPN536 (doses ranging from 0.1 to 10 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HPN536
Number of subjects: 0
Study: 33262580

Group type: EXPERIMENTAL
Intervention: COACHMAN intervention (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Enhanced usual care (n = 30)
Number of subjects: 60
Study: 33262641

Group type: EXPERIMENTAL
Intervention: Tolperisone 50 mg TID
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Tolperisone 100 mg TID
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Tolperisone 150 mg TID
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Tolperisone 200 mg TID
Number of subjects: 415

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 415
Study: 33262925

Group type: EXPERIMENTAL
Intervention: COPD.Pal® app (self-management app for COPD)
Number of subjects: 11
Study: 33263026

Group type: EXPERIMENTAL
Intervention: Presence of sarcoid-like granulomas
Number of subjects: 133
Study: 33263037

Group type: EXPERIMENTAL
Intervention: gefapixant 15 mg
Number of subjects: 2044

Group type: EXPERIMENTAL
Intervention: gefapixant 45 mg
Number of subjects: 2044

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2044
Study: 33263165

Group type: EXPERIMENTAL
Intervention: Adalimumab biosimilars (FKB327, ABP 501, BI 695501, GP2017, MSB11022, PF-06410293, SB5)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Switching between a biosimilar and the adalimumab RP
Number of subjects: 7
Study: 33263318

Group type: EXPERIMENTAL
Intervention: MLC tracking for lung SABR
Number of subjects: 17
Study: 33263499

Group type: EXPERIMENTAL
Intervention: Lean-and-Release test
Number of subjects: 26
Study: 33263626

Group type: EXPERIMENTAL
Intervention: Overnight Digital Monitoring (ODM) using a wireless high-resolution oximeter
Number of subjects: 304

Group type: COMPARATOR
Intervention: Polysomnography (PSG)
Number of subjects: 304
Study: 33263893

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of Care (SoC) alone
Number of subjects: 0
Study: 33264119

Group type: EXPERIMENTAL
Intervention: Norepinephrine administered during anesthesia (μg·kg-1 30 min-1)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: E/e' ratio during anesthesia
Number of subjects: 200
Study: 33264183

Group type: EXPERIMENTAL
Intervention: Anti-tumor necrosis factor therapy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: No activity limitations at diagnosis
Number of subjects: 30

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 30
Study: 33264327

Group type: EXPERIMENTAL
Intervention: Elevated preoperative liver cT1 (indicative of fibroinflammation)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Composite score combining FLR and cT1
Number of subjects: 143
Study: 33264515

Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33267723

Group type: EXPERIMENTAL
Intervention: Telehealth appointments
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Antihypertensive medications
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: General experiences during COVID-19
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Willingness to return to primary care clinic
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Compliance with health guidelines
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Access to healthcare
Number of subjects: 587
Study: 33267793

Group type: EXPERIMENTAL
Intervention: GDM group
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: M group
Number of subjects: 69

Group type: COMPARATOR
Intervention: C group
Number of subjects: 69
Study: 33267904

Group type: EXPERIMENTAL
Intervention: Advance directives (ADs)
Number of subjects: 8

Group type: COMPARATOR
Intervention: No advance directives (without ADs)
Number of subjects: 8
Study: 33267919

Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Cognitive-behavior therapy (CBT-E)
Number of subjects: 97
Study: 33267959

Group type: EXPERIMENTAL
Intervention: Follitropin delta coadministered with HP-hMG (dosage adjustments confined to HP-hMG only)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Follitropin delta coadministered with HP-hMG
Number of subjects: 110

Group type: COMPARATOR
Intervention: Follitropin delta from ESTHER-1 trial
Number of subjects: 110
Study: 33268029

Group type: EXPERIMENTAL
Intervention: Haploidentical natural killer (NK) cell infusions after autologous stem cell transplant (ASCT)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Haploidentical natural killer (NK) cell infusions
Number of subjects: 10
Study: 33268421

Group type: EXPERIMENTAL
Intervention: PharMoG team intervention (clinical medication review)
Number of subjects: 0
Study: 33268442

Group type: EXPERIMENTAL
Intervention: iRMD-COVID-19 patients hospitalized
Number of subjects: 694

Group type: EXPERIMENTAL
Intervention: Corticosteroids use in iRMD patients
Number of subjects: 694

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil use in iRMD patients
Number of subjects: 694

Group type: EXPERIMENTAL
Intervention: Rituximab use in iRMD patients
Number of subjects: 694

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 694

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 694

Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 694

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 694
Study: 33269010

Group type: EXPERIMENTAL
Intervention: Moroctocog alfa (AF-CC) on-demand treatment
Number of subjects: 138
Study: 33269506

Group type: EXPERIMENTAL
Intervention: MeRes100 sirolimus-eluting bioresorbable vascular scaffold (BRS)
Number of subjects: 64
Study: 33269549

Group type: EXPERIMENTAL
Intervention: LENT index (combination of LE index and NT-proBNP levels)
Number of subjects: 772

Group type: EXPERIMENTAL
Intervention: Admission NT-proBNP levels
Number of subjects: 772

Group type: EXPERIMENTAL
Intervention: Discharge NT-proBNP levels
Number of subjects: 772
Study: 33269625

Group type: EXPERIMENTAL
Intervention: linagliptin add-on therapy
Number of subjects: 3372
Study: 33270028

Group type: EXPERIMENTAL
Intervention: Serious video game (Land of Secret Gardens)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Comparison group (no game)
Number of subjects: 55
Study: 33270130

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 2256

Group type: COMPARATOR
Intervention: Laparoscopic gastric banding (LAGB)
Number of subjects: 2256
Study: 33270471

Group type: EXPERIMENTAL
Intervention: Platelet aggregation by light transmittance aggregometry; circulating levels of soluble CD40 ligand (sCD40L) measured at three time points (T1, T2, T3).
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (11 patients with negative SARS-CoV-2); same clinical presentation.
Number of subjects: 54
Study: 33270528

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 33270816

Group type: EXPERIMENTAL
Intervention: leukemia-specific T cells (mLSTs) administered at escalating doses (0.5 to 10 × 10^7 cells per square meter)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: leukemia-specific T cells (mLSTs)
Number of subjects: 25
Study: 33270832

Group type: EXPERIMENTAL
Intervention: Eculizumab discontinuation
Number of subjects: 55

Group type: COMPARATOR
Intervention: Eculizumab
Number of subjects: 55
Study: 33270906

Group type: COMPARATOR
Intervention: Zoledronic acid
Number of subjects: 5240

Group type: COMPARATOR
Intervention: Denosumab
Number of subjects: 5240
Study: 33271094

Group type: EXPERIMENTAL
Intervention: GX-188E therapeutic DNA vaccine plus pembrolizumab
Number of subjects: 36
Study: 33272030

Group type: EXPERIMENTAL
Intervention: Self-expandable nitinol stents
Number of subjects: 379
Study: 33272031

Group type: EXPERIMENTAL
Intervention: Evolut PRO or Evolut PRO+ transcatheter heart valves (THVs)
Number of subjects: 81
Study: 33272037

Group type: EXPERIMENTAL
Intervention: RBC transfusion
Number of subjects: 2587

Group type: COMPARATOR
Intervention: No RBC transfusion
Number of subjects: 2587
Study: 33272131

Group type: EXPERIMENTAL
Intervention: PF-05230907 at 30 μg/kg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: PF-05230907 at doses ranging from 5 to 30 μg/kg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: PF-05230907
Number of subjects: 21
Study: 33272133

Group type: EXPERIMENTAL
Intervention: Aneurysmal subarachnoid hemorrhage (aSAH) patients
Number of subjects: 1787
Study: 33272236

Group type: EXPERIMENTAL
Intervention: Stretched position
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Relaxed position
Number of subjects: 20
Study: 33272295

Group type: EXPERIMENTAL
Intervention: HDL from diabetic patients with CAD
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: C-HDL (in-vitro carbamylated HDL)
Number of subjects: 148

Group type: COMPARATOR
Intervention: HDL-CBL level in T2DM patients
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: HDL-CBL level in T2DM patients with CAD
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Higher HDL-CBL level
Number of subjects: 148
Study: 33272982

Group type: EXPERIMENTAL
Intervention: Nivolumab (1 mg/kg) and Ipilimumab (3 mg/kg) combined with Infliximab (5 mg/kg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Nivolumab (1 mg/kg) and Ipilimumab (3 mg/kg) combined with Certolizumab
Number of subjects: 14
Study: 33273034

Group type: EXPERIMENTAL
Intervention: Variant-specific loss of heterozygosity (LOH) analysis
Number of subjects: 0
Study: 33273214

Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Number of subjects: 274
Study: 33273317

Group type: EXPERIMENTAL
Intervention: Cross-sectional cohort (CSC)
Number of subjects: 1027

Group type: COMPARATOR
Intervention: Prospective cohort (PC)
Number of subjects: 1027
Study: 33273485

Group type: EXPERIMENTAL
Intervention: Dried blood spot (DBS) sampling and CRP test regime
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Continuous weekly DBS CRP data
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Minimal baseline and 6 week sample CRP data
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: DBS ELISA assay CRP measures
Number of subjects: 100
Study: 33273742

Group type: EXPERIMENTAL
Intervention: MK-4482/EIDD-2801, dosage and duration not specified
Number of subjects: 0
Study: 33274309

Group type: EXPERIMENTAL
Intervention: Pomegranate juice (PomJ)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo drink (PL)
Number of subjects: 20
Study: 33274349

Group type: EXPERIMENTAL
Intervention: Exercise-induced modulation
Number of subjects: 0
Study: 33274416

Group type: EXPERIMENTAL
Intervention: COVID-19
Number of subjects: 213

Group type: COMPARATOR
Intervention: Influenza
Number of subjects: 213
Study: 33274648

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33274668

Group type: EXPERIMENTAL
Intervention: Detail and Flexibility Questionnaire (DFlex)
Number of subjects: 0
Study: 33274726

Group type: EXPERIMENTAL
Intervention: Personalized mobile app with text, voice, video, and pictorial messages regarding routine childhood immunization (RCI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 33274751

Group type: EXPERIMENTAL
Intervention: Blood lead (BL) ratio in the digit-symbol test (DST) cohort
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Blood lead (BL) ratio in the Stroop test (ST) cohort
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Changes in DST and ST test results with blood lead changes
Number of subjects: 260
Study: 33275104

Group type: EXPERIMENTAL
Intervention: Twitter + Fitbit treatment group
Number of subjects: 45

Group type: COMPARATOR
Intervention: Fitbit-only control group
Number of subjects: 45